Changes in serum receptor activator of nuclear factor-κb ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid- induced osteoporosis treated with human parathyroid hormone (1-34)

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 7, 2004, Pages 3332-3336

  Buxton, Eric C ^a   Yao, Wei ^a   Lane, Nancy E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; GLUCOCORTICOID; HORMONE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; CARRIER PROTEINS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GLYCOPROTEINS; HUMANS; INTERLEUKIN-6; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOPOROSIS; OSTEOPROTEGERIN; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; TIME FACTORS;

EID: 3242667700     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-032066     Document Type: Article

References (26)

1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
2. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555
3. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lane TL, Garnero P, Bouxsein ML, Biliezikian J, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
4. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
5. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 344:1434-1441
6. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D 1997 A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82:620-628
7. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD 2000 Short term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11:434-442
8. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627-1633
9. Khosla S 2001 Minireview. the OPG/RANKL/RANK system. Endocrinology 142:5050-5055
10. Lee SK, Lorenzo JA 1999 Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140:3552-3561
11. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE 2001 Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054
12. Locklin RM, Khosla S, Turner RT, Riggs BL 2003 Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 89:180-190
13. Horwood NJ, Elliott J, Martin TJ, Gillespie MT 1998 Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139:4743-4746
14. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, McClure D, Seno G, Churgay L, Chandrasekhar S, Martin TJ 2000 In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15:863-871
15. Fu Q, Jilka RL, Manolagas SC, O'Brien CA 2002 Parathyroid hormone stimulates receptor activator of NF-κB ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 277:48868-48875
16. Vidal NO, Brandstrom H, Jonsson KB, Ohlsson C 1998 Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol 159:191-195
17. Sasaki N, Kusano E, Ando Y, Nemoto J, Iimura O, Ito C, Takeda S, Yano K, Tsuda E, Asano Y 2002 Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. Bone 30:853-858
18. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 Stimulation of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoids-induced osteoporosis. Endocrinology 140:4377-4381
19. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA 2003 Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32:1-7
20. Mitnick MA, Grey A, Masiukiewicz U, Bartkiewicz M, Rios-Velez L, Friedman S, Xu L, Horowitz MC, Insogna K 2001 Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. Am J Physiol Endocrinol Metab 280:E405-E412
21. Pollock JH, Blaha MJ, Lavish SA, Stevenson S, Greenfield EM 1996 In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of iterleukin-6 and leukemia inhibitory factor. J Bone Miner Res 11:754-759
22. Li NH, Ouchi Y, Okamoto Y, Masuyama A, Kaneki M, Futami A, Hosoi T, Nakamura T, Orimo H 1991 Effect of parathyroid hormone on release of interleukin 1 and interleukin 6 from cultured mouse osteoblastic cells. Biochem Biophys Res Commun 179:236-242
23. Greenfield EM, Shaw SM, Goraik SA, Banks MA 1995 Adenyl cyclase and interleukin-6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest 96:1238-1244
24. Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K 1996 Circulating levels of interleukin-6 and tumor necrosis factor-α are elevated in primary hyperparathyroidism and correlate with markers of bone resorption - a clinical research center study. J Clin Endocrinol Metab 81:3450-3454
25. Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K 2002 Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 87:4946-4951
26. Masiukiewicz US, Mitnick M, Gulanski BI, Insogna KL 2002 Evidence that the IL-6/IL-6 soluble receptor cytokine system plays a role in the increased sensitivity to PTH in estrogen-deficient women. J Clin Endocrinol Metab 87:2892-2898